Tristel PLC
23 December 2005
Tristel PLC ('Tristel' or the 'Company')
23 December 2005
Grant of Options
Tristel, the AIM listed provider of infection control products, announces that
it has granted options to employees over 660,000 ordinary shares of 1p each
('Shares'), under the Company's EMI Option Scheme. The options have an exercise
price of 53.75p and vest 25% from today and then in 3 equal tranches on 23
December over the following three years. The options, once vested, can be
exercised by 23 December 2015.
In addition Paul Swinney, Chief Executive Officer, has been granted options over
250,000 Shares under the Unapproved Option Scheme. The options have an exercise
price of 59.5p, vesting 25% from today and then in 3 equal tranches on 23
December over the following three years. The options, once vested, must be
exercised by 23 December 2015. Paul Swinney does not have any other options and
is currently interested in 2,713,986 Shares, being 11.39% of the Company's
issued share capital.
For further details please contact:
Teather & Greenwood Limited
Robert Naylor / Harry Nicholas
Tel: 020 7426 9000
This information is provided by RNS
The company news service from the London Stock Exchange ZZFGGKZM
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.